Smoking Status Does Not Contraindicate Antiarrhythmic Drugs
Smoking is NOT a contraindication to antiarrhythmic drugs, including Class IC agents like flecainide or propafenone. There is no evidence in current guidelines, FDA labeling, or clinical literature that smoking status affects the safety or efficacy of antiarrhythmic medications.
Actual Contraindications to Class IC Agents
The contraindications to flecainide and propafenone are based on cardiac structural abnormalities and conduction system disease, not smoking status:
Absolute Contraindications 1, 2, 3:
- Heart failure with reduced ejection fraction (HFrEF)
- Coronary artery disease (CAD) - particularly recent myocardial infarction or active ischemia
- Severe left ventricular hypertrophy
- Sinus node dysfunction or AV conduction disturbances (without pacemaker)
- Cardiogenic shock
- Marked hypotension
- Bronchospastic disorders (propafenone)
The Evidence Base
The 2024 ESC Guidelines explicitly state: "Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease" 1. Smoking is conspicuously absent from this list.
The FDA labeling for both flecainide 2 and propafenone 3 lists specific cardiac contraindications but makes no mention of smoking as a risk factor or contraindication.
Common Pitfall: Confusing Structural Heart Disease with Smoking
The restriction on Class IC agents stems from the 1991 CAST trial, which showed increased mortality in post-MI patients with ventricular ectopy and reduced ejection fraction 2. This has been inappropriately extrapolated to all smokers, but smoking alone—without structural heart disease—does not increase proarrhythmic risk with these agents.
Patient Selection Algorithm:
Before prescribing Class IC agents, assess for:
- Left ventricular function - Echo to confirm normal/preserved EF
- Coronary disease - History of MI, angina, or need for stress testing if risk factors present
- Structural abnormalities - LV hypertrophy on echo
- Conduction system - Baseline ECG for AV block, bundle branch block, or QRS >120ms
If all above are normal → Class IC agents are appropriate regardless of smoking status
Emerging Evidence on Previously Restricted Populations
Recent data 4, 5, 6 suggest that even the traditional contraindication in stable CAD may be overly restrictive in carefully selected patients with preserved ventricular function and no active ischemia. A 2026 meta-analysis found no increased ventricular arrhythmia risk with Class IC agents in structural heart disease populations 4, though this remains hypothesis-generating and not yet incorporated into guidelines.
The bottom line: Screen for structural heart disease and conduction abnormalities, not smoking status, when considering Class IC antiarrhythmics.